What is Rectify Pharmaceuticals?
Based in Cambridge, Massachusetts, Rectify Pharmaceuticals operates at the intersection of genetic science and drug discovery. The company specializes in the development of Positive Functional Modulators (PFMs), a novel class of precision therapeutics designed to restore the function of ABC transporters. By targeting the root cause of serious genetic diseases rather than merely managing symptoms, Rectify is carving out a distinct niche in the biotechnology sector. Their platform technology represents a sophisticated evolution in therapeutic intervention, aiming to correct cellular dysfunction with high specificity and efficacy.
How much funding has Rectify Pharmaceuticals raised?
Rectify Pharmaceuticals has raised a total of $100M across 1 funding round:
Series A
$100M
Series A (2021): $100M with participation from Omega Fund Management, Forbion, and Atlas Venture
Key Investors in Rectify Pharmaceuticals
Forbion
Forbion is a global life sciences venture capital firm that specializes in guiding biotech and biopharmaceutical companies from early-stage research through clinical development.
Atlas Venture
Atlas Venture is a pioneering early-stage venture capital firm focused on creating and building breakthrough biotechnology companies that translate cutting-edge science into life-changing medicines.
Omega Fund Management
Omega Fund Management is a specialized investment firm that focuses on identifying and supporting high-potential companies within the life sciences and biotechnology sectors.
What's next for Rectify Pharmaceuticals?
Looking ahead, the strategic deployment of this capital will likely focus on scaling the company's R&D infrastructure and advancing its lead candidates through preclinical and early clinical milestones. As Rectify Pharmaceuticals continues to refine its PFM platform, the focus will shift toward establishing clinical proof-of-concept and expanding its intellectual property portfolio. The involvement of seasoned life science investors suggests a long-term commitment to building a sustainable biopharmaceutical entity capable of navigating the complex regulatory and development pathways inherent in genetic medicine. Future growth will be defined by the company's ability to translate its scientific breakthroughs into tangible patient outcomes, thereby validating its market position as a leader in the next generation of genetic therapeutics.
See full Rectify Pharmaceuticals company page
